Kexing Biopharm's Licensed-In Product, Infliximab, Receives Marketing Approval in Malaysia

Article source：Dec 10,2025View： 13

Recently, the Reminton (Infliximab for Injection) licensed in by the company from Mabpharm Limited has been approved for marketing by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. As of now, Reminton (Infliximab for Injection) has successfully gained access in multiple countries, including Peru, Bangladesh, and Pakistan, with its internationalization process advancing rapidly.

Reminton (Infliximab for Injection) was approved for marketing by the National Medical Products Administration in July 2021 (Approval No.: H20210025), marking the first infliximab biosimilar approved in China. It is indicated for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease in adults and children aged 6 and above, fistulizing Crohn's disease, and ulcerative colitis in adults.

In recent years, Kexing Biopharm has focused on oncology and autoimmune diseases, successively reaching overseas commercialization agreements with several renowned domestic pharmaceutical companies for multiple products. This not only leads high-quality Chinese medicines to go global but also continuously injects new momentum into the company's globalization efforts.

About Kexing

Kexing Biopharm (Stock Code: 688136.SH) is a innovative and international biopharmaceutical enterprise that engages in the R&D, manufacture and sales of innovative medicines of distinct modalities including recombinant proteins, antibodies, and targeted delivery therapies.

Through building cutting-edge technology platforms to advance the development of novel targeted therapies and drug delivery systems, Kexing strives to address unmet clinical needs in the areas of oncology, autoimmune and antiviral treatment, creating a significant and meaningful positive impact on patients' lives.

By adhering to the platform development model driven by the twin engines of “Innovation & Internationalization”, Kexing is committed to becoming a world leader in high-quality biopharmaceuticals, improving the health of patients worldwide.